Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31495252 | 0.98 | PTPN1 (0.46) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL11279790 | 0.84 | APLNR (0.40) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL31495253 | 0.84 | PTPN1 (0.46) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL19386509 | 0.74 | PTPN1 (0.46) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL10781942 | 0.74 | MAOA (0.64) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL17969772 | 0.73 | PTPN1 (0.41) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL10782026 | 0.72 | MAOA (0.52) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL30770696 | 0.72 | MAOA (0.52) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL30770716 | 0.70 | MAOA (0.50) | PTPN1PTPRCPTPRFCDC25BMAOA | |
| SCHEMBL30770641 | 0.70 | MAOA (0.50) | PTPN1PTPRCPTPRFCDC25BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022089-A1 | QUINONE-DERIVED COMPOUNDS AND USE THEREOF AGAINST LEISHMANIA SPP | UNIVERSIDAD DE LA LAGUNA (ES) | 2026-01-22 | — | — | US | disclosed |
| EP-4549425-A1 | QUINONE-DERIVED COMPOUNDS AND USE THEREOF AGAINST LEISHMANIA SPP | Universidad de la Laguna (ES) | 2025-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022089-A1 | QUINONE-DERIVED COMPOUNDS AND USE THEREOF AGAINST LEISHMANIA SPP | G6PD, SDHA, DHPS | PTPN1 3566/4885PTPRC 3120/4885PTPRF 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.